Product approval information is indicated for the treatment of primary immunodeficiency (PI) associated with defects in humoral immunity, in adults and children two years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/fH59V0U
No comments:
Post a Comment